Showing 6,901 - 6,920 results of 7,348 for search 'significantly ((((linear decrease) OR (((we decrease) OR (nn decrease))))) OR (larger decrease))', query time: 0.57s Refine Results
  1. 6901

    Assessing the Causal Role of Walking Pace and Hand Grip Strength with Chronic Obstructive Pulmonary Disease Hospital: A Mendelian Randomization Study by Lu Wang (45927)

    Published 2024
    “…</p> <p>Our research shows a link between slower walking pace and higher COPD hospitalization risk, as well as decreased lung function (PEF, FEV1, FVC). We also found a significant correlation between weaker hand grip and reduced lung function, especially FVC. …”
  2. 6902

    Data Sheet 1_Cardiac T1 mapping in non-ST-segment elevation myocardial infarction: temporal changes in myocardial fibrosis.pdf by Luis Paiva (7175234)

    Published 2025
    “…</p>Conclusions<p>After NSTEMI, LGE decreased in the heart regions supplied by the culprit coronary arteries. …”
  3. 6903

    Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”
  4. 6904

    Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”
  5. 6905

    Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”
  6. 6906

    Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”
  7. 6907

    Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”
  8. 6908

    Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”
  9. 6909

    Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”
  10. 6910

    Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”
  11. 6911

    Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”
  12. 6912

    Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”
  13. 6913

    Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”
  14. 6914

    Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…</p>Methods<p>We conducted a 48-month longitudinal, retrospective cohort study of 54 patients with CTP B cirrhosis secondary to MASLD and T2DM who were initiated on SGLT2i (n=27) or insulin (n=27). …”
  15. 6915

    Disturbances in drylands: Interactions among herbivory, drought, and termite activity in savanna plant communities by Harry Wells (11430190)

    Published 2025
    “…The impacts of these events may be modulated by biotic agents in unpredictable ways, yet few experiments cover sufficient spatiotemporal scales to measure the interactive effects of multiple extreme events. We used 15 years of a 28-year experiment spanning several significant droughts to investigate how rainfall, large herbivores, and soil-engineering termites affect understory vegetation in a semi-arid savanna. …”
  16. 6916

    Video 1_Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review.mp4 by Xin Fei (20466992)

    Published 2024
    “…After treatment, the patient’s symptoms were controlled, tumor marker levels decreased, and imaging showed significant improvement. …”
  17. 6917

    Image 1_Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review.jpeg by Xin Fei (20466992)

    Published 2024
    “…After treatment, the patient’s symptoms were controlled, tumor marker levels decreased, and imaging showed significant improvement. …”
  18. 6918

    Video 2_Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review.mp4 by Xin Fei (20466992)

    Published 2024
    “…After treatment, the patient’s symptoms were controlled, tumor marker levels decreased, and imaging showed significant improvement. …”
  19. 6919

    Table 4_Inoculation frequency and maize genotype influence plant growth-promoting effects of soil bacteria under low nitrogen conditions.xlsx by Lexie R. Foster (22235653)

    Published 2025
    “…This was carried out through non-repeated and repeated bacterial inoculations using different maize genotypes. We identified several growth-promoting bacterial isolates and observed a significant interaction between the bacterial isolates and the maize genotype, suggesting a strong interaction between the host genetics and the effects of bacterial isolates. …”
  20. 6920

    Dataset and R code for Humann-Guilleminot et al. - Dose-dependent effects of cadmium on food consumption, mass, and bioaccumulation in the moth <i>Spodoptera littoralis.</i> by Ségolène Humann-Guilleminot (20908844)

    Published 2025
    “…In addition, our results indicated that cadmium accumulation reached its maximum at pupal stage and decreased in adults, suggesting that efficient detoxification processes occur during metamorphosis, with significant amounts of cadmium that were excreted through the integument and exuviae at the pre-pupal stage. …”